Ahmedabad, India – February 5, 2025 – Lincoln Pharmaceuticals Limited has announced that its Board of Directors will convene on February 13, 2025, to review and approve the unaudited standalone and consolidated financial results for the quarter ended December 31, 2024.
Key Details of the Upcoming Board Meeting
- Meeting Date: February 13, 2025
- Agenda: Approval of unaudited financial results for Q3 FY25 (December 2024 quarter)
- Nature of Financials: Standalone and consolidated
- Reporting Period: Quarterly
- Trading Window Closure:
- Start Date: January 1, 2025
- End Date: February 15, 2025
The results will provide investors with insights into Lincoln Pharmaceuticals' financial health and performance during the December quarter of FY2025.
Investors and stakeholders are advised to track further announcements post the Board meeting for detailed financial disclosures.